Status:
COMPLETED
Inflammation, Epigenetics in CHF Patients With AF
Lead Sponsor:
University of Palermo
Conditions:
Congestive Heart Failure Chronic
Atrial Fibrillation (Permanent)
Eligibility:
All Genders
18+ years
Brief Summary
the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF * The serum levels of some candidate cytokine variables and their relationship with ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- ≥18 years
- Left ventricular ejection fraction \>40%
- New York Heart Association class II-IV symptoms
- NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography
- Exclusion Criteria
- \- Other AF subtypes (paroxysmal, persistent, long-standing persistent)
- At least one of the following criteria:
- Acute heart failure
- NYHA IV
- NT-proBNP \>4000 pg/mL
- Significant valvular disease
- Mechanical prosthesis
- Cardiovascular implantable devices
- Active malignancy
- Inflammatory or infectious diseases
- Severe renal (eGFR \<30 mL/min/m²) or hepatic failure
- Chronic steroid/anti-inflammatory therapy
Exclusion
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
164 Patients enrolled
Trial Details
Trial ID
NCT07152301
Start Date
January 1 2020
End Date
May 31 2022
Last Update
September 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine and Stroke Care Ward, Policlinic Hospital of Palermo, Sicily
Palermo, PA, Italy, 90127